Infections and Psoriasis Treatment: More "Real-World" Data Needed with Critical Appraisal.
Data from the Spanish registry BIOBADADERM suggest that the risks of any infectious episode in patients treated with biologics are limited, not exceeding the risks observed with a conventional treatment such as cyclosporine. The registry lacked enough statistical power to analyze risks for severe infections. These should be the focus of further research, although the difficulties of "real-world" data analysis should not be trivialized.